A carregar...
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
In 1997, for the first time in history, a monoclonal antibody (mAb), i.e., the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug Administration for use in cancer patients. Since then, the panel of mAbs that are approved by international regulatory agencies for the treatment...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Landes Bioscience
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3937194/ https://ncbi.nlm.nih.gov/pubmed/24605265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.27048 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|